Nebulized treprostinil (Tyvaso) reduced lung function decline from idiopathic pulmonary fibrosis (IPF) in the pivotal TETON-1 ...

About 40% of at-risk patients with COPD did not receive maintenance therapy despite having frequent or severe exacerbations.

Two phase 3, randomized trials of inhaled treprostinil for idiopathic pulmonary fibrosis (IPF) were conducted on the basis of preclinical and clinical evidence of an antifibrotic mechanism.

Pairing vulnerable, low-income patients with asthma coaches can improve outcomes and may also reduce costs associated with ...

Data from Phase 2a study of LAM-001 on top of standard of care in PH-ILD patients with refractory PH demonstrated clinically ...

Acquisition includes LAM-001, an inhaled formulation of rapamycin for multiple pulmonary diseases, including pulmonary hypertension associated ...

Clinical Trial Results in Pulmonary Medicine Advance Outcomes session, TETON-1 evaluated inhaled treprostinil in patients ...

Bank of America Global Healthcare Conference 2026 May 13, 2026 11:40 AM EDTCompany ParticipantsMichael Kaseta - COO ...

If you have chronic obstructive pulmonary disease (COPD)—an umbrella term for several lung diseases, including emphysema, ...

If you rely on inhalers like Ohtuvayre, Albuterol, or Pulmicort, 2026 has brought a complex mix of challenges and new options. While manufacturers like Amneal have finally launched new generic ...

This biotech firm develops therapies for rare pulmonary diseases, leveraging proprietary drug delivery technology in the U.S.